Find activities

103 results

  • MSAC Consultation Survey - Application 1823

    MSAC application 1823 177 Lutetium PSMA-617 for prostate specific membrane antigen (PSMA)-positive, taxane-naïve patients with metastatic castrate resistant prostate cancer (mCRPC). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1822

    MSAC application 1822 F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for evaluation of complex infection. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1825

    MSAC application 1825 Transcranial Doppler bubble test for patent foramen ovale. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It does this by... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1821

    MSAC application 1821 Testing for Chromogranin A in patients with neuroendocrine neoplasms. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1826

    MSAC application 1826 N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) testing to support management of patients with heart failure. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1820

    MSAC application 1820 In situ hybridisation (ISH) testing of tumour tissue to detect viral genomes (EBV and HPV). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1738.1

    MSAC application 1738.1 Investigations to support the use of PBS subsidised lecanemab in people with mild cognitive impairment and mild dementia due to Alzheimer’s disease. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed... More
    Opened 29 May 2026

  • MSAC Consultation Survey - Application 1827

    MSAC application 1827 Testing for hepatitis B virus (HBV) and hepatitis B virus surface antigen (HBsAg) to support the use of PBS subsidised bepirovisen in people with chronic hepatitis B (CHB). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better... More
    Opened 29 May 2026

  • Framework for consumer engagement in HTA

    We are developing a framework that sets out guiding principles, focus areas and actions to support better consumer engagement in HTA. We'd like to hear your thoughts on the framework and how it could be improved. We will summarise your responses and share the findings so you can see what we heard and how we used the feedback to improve the framework. If you have difficulty responding online, please email htaconsumerengagement@health.gov.au . View the... More
    Closed 26 May 2026

  • Public consultation on items to be considered by the PBAC (July 2026)

    Consultation has opened for the July 2026 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines and vaccines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Information provided by consumers helps the committee... More
    Closed 20 May 2026

  • MSAC Consultation Survey - Application 1818

    MSAC Application 1818 – Expansion of specialist supervision criteria for MBS and PBS items for integrated, closed-system, extracorporeal photopheresis and methoxsalen (UVADEX®) for the treatment of Cutaneous T-Cell Lymphoma and chronic Graft Versus Host Disease. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). ... More
    Opened 1 April 2026

  • MSAC Consultation Survey - Application 1816

    MSAC application 1816 Genetic testing to detect estrogen receptor 1 (ESR1) variants in patients with hormone receptor (HR)-positive, HER-2 negative, locally advanced or metastatic breast cancer to determine eligibility for treatment with PBS subsidised camizestrant. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). ... More
    Closed 13 March 2026

  • MSAC Consultation Survey - Application 1815

    MSAC application 1815 Computed tomography (CT) of the coronary arteries to determine coronary artery calcium score. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health... More
    Closed 13 March 2026

  • MSAC Consultation Survey - Application 1814

    MSAC application 1814 Bronchoscopic lung volume reduction with endobronchial valves for the treatment of severe emphysema. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian... More
    Closed 13 March 2026

  • MSAC Consultation Survey - Application 1813

    MSAC application 1813 Detection of measurable residual disease in patients with acute myeloid leukaemia. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Closed 13 March 2026

  • MSAC Consultation Survey - Application 1659.1

    MSAC application 1659.1 Catheter-based renal denervation for uncontrolled elevated systolic blood pressure. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1782.1

    MSAC application 1782.1 Genetic testing to detect estrogen receptor 1 (ESR1) variants in patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). ... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1795

    MSAC application 1795 Positron emission tomography / computed tomography (PET/CT) dopaminergic imaging for evaluating Parkinsonism. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1793

    MSAC application 1793 Diagnostic genomic testing for fetal anomalies Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It does this by providing MSAC... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1786 - resubmission

    A further period of consultation is open on application 1786 – FreeStyle Libre 2 continuous glucose monitoring (CGM) System for people with insulin-dependent type 2 diabetes, gestational diabetes and type 3c diabetes, for consideration by the Medical Services Advisory Committee (MSAC) and its Evaluation Subcommittee (ESC). Consultation input helps MSAC and its subcommittees to better understand how a proposed health service or technology fits in the Australian health care environment. ... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1812

    MSAC application 1812 Transcatheter Edge-To-Edge Repair (TEER) for the treatment of severe tricuspid regurgitation (TR) using the TriClip device. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1785 - resubmission

    A further period of consultation is open on application 1785 – Dexcom ONE+ Continuous Glucose Monitoring (CGM) System for people with insulin-dependent type 2 diabetes, for consideration by the Medical Services Advisory Committee (MSAC) and its Evaluation Subcommittee (ESC). Consultation input helps MSAC and its subcommittees to better understand how a proposed health service or technology fits in the Australian health care environment. MSAC previously considered application... More
    Opened 25 February 2026

  • MSAC Consultation Survey - Application 1817

    MSAC application 1817 Xeomin (incobotulinumtoxinA) injection codes for lower limb spasticity following an acute event. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health... More
    Closed 20 February 2026

  • MSAC Consultation Survey - Application 1790

    MSAC application 1790 POLE genotyping for the molecular classification of endometrial cancer. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It... More
    Closed 13 February 2026

  • MSAC Consultation Survey - Application 1796

    MSAC application 1796 ADAMTS13 testing for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Closed 13 February 2026

  • MSAC Consultation Survey - Application 1804

    MSAC application 1804 - Genetic testing to detect RET variants in patients with medullary thyroid cancer to determine eligibility for PBS subsidised selpercatinib treatment. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed... More
    Closed 13 February 2026

  • MSAC Consultation Survey - Application 1805

    MSAC application 1805 - Concizumab for routine prophylaxis to prevent bleeding in patients with haemophilia B. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Closed 13 February 2026

  • MSAC Consultation Survey - Application 1806

    MSAC application 1806 - Marstacimab for routine prophylaxis to prevent bleeding in patients with haemophilia. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care ... More
    Closed 13 February 2026

  • MSAC Consultation Survey - Application 1657.1

    MSAC application 1657.1 Rhenium-188 brachytherapy for non-melanoma skin cancer. Consultation is open on applications for consideration by the Medical Services Advisory Committee (MSAC) and its sub-committees — the PICO Advisory Sub-Committee (PASC) and Evaluation Sub-Committee (ESC). Consultation input helps MSAC and its sub-committees to better understand how a proposed health service or technology fits in the Australian health care environment. It does this by... More
    Closed 13 February 2026

  • Public consultation on items to be considered by the PBAC (March 2026)

    Consultation has opened for the March 2026 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines and vaccines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented by the applicant. Information provided by consumers helps the committee... More
    Closed 21 January 2026
103 results. Page 1 of 4